Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers
- 11A Consulting, Dr Wach & Wach GbR, Weil am Rhein, Germany
- 2Zambon Biotech SA, Medical Affairs, Cadempino, Switzerland
- 3Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, SE1 1UL UK
Abstract
Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00702-026-03233-w.
Related
- Comparing Machine Learning and Population Pharmacokinetic Approaches for Drug Concentration Prediction in Dense and Sparse Data Settings
- Randomized, Controlled, Crossover Trial Comparing Immediate Effects of Components of Complex Decongestive Therapy in Lower-limb Lymphedema Patients.
- Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients
- Comparing aggregated and nonlinear measures of coordinative behaviors in immediate responder first aid groups: a controlled experimental simulation study.
- Buccal and sublingual lyophilised naloxone for opioid overdose reversal: A Phase 1 open-label, random-sequence crossover pharmacokinetic study protocol in healthy volunteers (NalBuc)
BibTeX
@article{wach2026population,
title = {{Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers}},
author = {Achim Wach and Jaakko Kopra and Ivan Marjanovic and Mathias Knecht and Peter Jenner},
journal = {Journal of Neural Transmission},
year = {2026},
month = jul,
doi = {10.1007/s00702-026-03233-w},
url = {https://doi.org/10.1007/s00702-026-03233-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers
AU - Achim Wach
AU - Jaakko Kopra
AU - Ivan Marjanovic
AU - Mathias Knecht
AU - Peter Jenner
PY - 2026
DA - 2026/07/21
JO - Journal of Neural Transmission
DO - 10.1007/s00702-026-03233-w
UR - https://doi.org/10.1007/s00702-026-03233-w
AB - Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00702-026-03233-w.
SN - 0300-9564
SN - 1435-1463
ER -